期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

间充质干细胞来源外泌体在肝疾病中的研究进展

Research progress of mesenchymal stem cell-derived exosomes in liver diseases
原文传递
导出
摘要 外泌体能够通过运送核酸、蛋白质和脂质等多种活性物质介导细胞间的相互作用。间充质干细胞(MSCs)来源外泌体能够通过其携带的活性物质发挥促进肝脏修复再生、抑制肝脏炎症和肝纤维化、调控肿瘤进展等重要作用,为临床肝病的治疗提供新策略。现就MSCs来源外泌体在肝脏疾病中的研究进展进行综述。 Exosomes can mediate cell-cell interactions by transporting various active substances such as nucleic acids,proteins,and lipids.Mesenchymal stem cell-derived exosomes(MSCs)can play important roles in promoting liver repair and regeneration through the active substances it carries,inhibiting liver inflammation and liver fibrosis,and regulating tumor progression,and thereby providing new therapeutic strategies for clinical liver diseases.This article reviews the research progress of MSCs-derived exosomes in liver diseases.
作者 叶海坤 张雅敏 Ye Haikun;Zhang Yamin(Hepatobiliary Surgery Department,Tianjin First Central Hospital,Tianjin 300192,China)
机构地区 天津市第一中心医院肝胆外科
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2022年第7期790-792,共3页 Chinese Journal of Hepatology
关键词 肝疾病 间充质干细胞 外泌体 生物学特性 功能 Liver diseases Mesenchymal stem cells Exosomes Biological characteristics Function
分类号 R575 [医药卫生—消化系统]
  • 相关文献

参考文献3

二级参考文献32

  • 1Debajit Dey,Manidipa Banerjee.Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis[J].Journal of Clinical and Translational Hepatology,2016,4(3):248-257. 被引量：4
  • 2Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6): 2099-2108. DOI: 10.1002/hep.27406.
  • 3Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period[J]. Int J Infect Dis, 2012, 16(2): e82-88. DOI: 10.1016/ j.ijid.2011.10.009.
  • 4Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures[J]. J Epidemiol, 2011, 21 (6): 401-416.
  • 5Feng G, Zhang JY, Zeng QL, et al. Interleukin-21 mediates hepatitis B virus-associated liver cirrhosis by activating hepatic stellate cells[J]. Hepatol Res, 2014, 44(10): E198-205. DOI: 10.1111/ hepr.12215.
  • 6Wu X, Zhang JY, Huang A, et al. Decreased V82 3'8 T cells associated with liver damage by regulation of Thl 7 response in patients with chronic hepatitis B[J]. J Infect Dis, 2013, 208(8): 1294- 1304. DOI: 10.1093/infdis/jit312.
  • 7Lin PC, Chiou TW, Lin ZS, et al. A proposed novel stem cell therapy protocol for liver cirrhosis[J]. Cell Transplant, 2015, 24(3): 533-540. DOI: 10.3727/096368915X687228.
  • 8Nakamura T, Torimura T, Iwamoto H, et al. CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis[J]. J Gastroenterol Hepatol. 2014, 29(10):1830-1838. DOI: 10.11 ll/jgh.12622.
  • 9Shi M, Fu J, Shi F, et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection[J]. Clin Immunol, 2009, 132(1): 43-54. DOI: 10.1016/j.clim.2009.03.001.
  • 10Ma YJ, He M, Han JA, et al. A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B[J]. Scand J Immunol, 2013, 78(4): 387-93. DOI: 10.1111/sji.12097.

共引文献25

中华肝脏病杂志
2022年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部